Kornimate/medical-research-clean huggingface dataset:
exploring the impact of dementia prevention programs using robots as intervention tools on community elderly

Conditions: Mild Cognitive Impairment (MCI); Dementia; Cognitive Decline; Psychological Well-being; Aging and Cognitive Health

Summary: the purpose of this study is to intervene in the cognitive functions of the community elderly through the "robot dementia prevention course" training. it is expected that through the eight-week course design activities, the cognitive functions, social activities, emotional management (such as alleviating depression), well-being, reduce loneliness and can be achieved, thereby preventing or delaying cognitive decline. this study is a quasi-experimental design. it adopts pre-test and post-test methods for the experimental group and the control group. before the intervention of the "robotic dementia prevention course", the community elderly were given a pre-test. after receiving an 8-week course (two months), the first post-test will be conducted, and three months later, the second post-test (post-post-test) will be conducted to analyze the delay effect. the experimental group conducted a two-month "robot dementia prevention course" intervention. the research subjects were 40 people. each group of 5 people was assigned a kebbi robot. the course intervention was divided into 8 groups. the kebbi robot mainly taught and communicated with the elderly interactively. there is a well-trained teaching assistant in the class to enhance the learning effect of the elderly. the two classes per week are about 2 hours long, with 50 minutes of course knowledge introduction, 10 minutes of rest, 50 minutes of interaction with kebbi artificial intelligence-based board games, and 10 minutes of prize-based quizzes after class. they are held once a week, with a total of 8 weeks of courses (duration two months), classes were taken in the elderly's original care center or long-term care base; the control group did not receive any course intervention. statistical methods were analyzed using spss version 23.0, and descriptive statistics, paired t tests, generalized estimating equations, etc. were used to test the changes before and after the intervention.


Eligibility criteria:
inclusion criteria: * age 65 years or older, able to communicate in mandarin or taiwanese, able to provide informed consent or have a legal guardian provide consent exclusion criteria: * diagnosis of severe dementia or advanced neurodegenerative disease, severe psychiatric disorders (e.g., schizophrenia, bipolar disorder), unconsciousness or inability to stay awake or focused for the session duration, inability to comply with study protocol or scheduled sessions

Keywords: robot-delivery intervention, dementia prevention, dementia, community elderly
evaluation of the accuracy of the abbott sensor based interstitial glucose monitoring system

Conditions: Type 1 Diabetes; Type 2 Diabetes

Summary: the purpose of this study is to demonstrate point accuracy of the abbott sensor based glucose monitoring (gm) system interstitial glucose results against reader capillary blood glucose (bg) reference using the consensus error grid. during the course of the wear duration, the subject is required to test fingerstick glucose measurement at least eight (8) times a day for capillary reference glucose measurements and three in-clinic visits of a maximum 13 hours each for venous reference glucose measurements. with every reference measurement, the subject or study staff will perform a measurement on the system.


Eligibility criteria:
inclusion criteria: 1. subject must be at least 18 years of age. 2. subject must have type 1 or type 2 diabetes for at least 2 years prior to enrollment. 3. subject must require insulin therapy through an insulin pump and/or multiple daily insulin injections (at least 3 injections daily) for at least 6 months prior to enrollment. 4. subject must be able to read and understand english. 5. in the investigator's opinion, the subject must be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol. 6. subject must be available to participate in all study visits. 7. subject must be willing and able to provide written signed and dated informed consent. exclusion criteria: 1. subject has known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin. 2. subject is pregnant, attempting to conceive or not willing and able to practice birth control during the study duration (applicable to female subjects only). 3. subject has skin lesions, scarring, redness, infection or edema at the application sites that could interfere with device placement or the accuracy of interstitial glucose measurements. 4. subject currently is participating in another clinical trial. 5. subject has donated blood within 112 days (3.7 months) prior to the beginning of the study activities. 6. subject has concomitant medical condition which, in the opinion of the investigator, could interfere with the study or present a risk to the safety or welfare of the subject or study staff. such conditions include but are not limited to: • history of hiv, hepatitis b or c 7. subject has a known medical condition that, in the opinion of the investigator, may increase the risk of bleeding. 8. subject has x-ray, mri or ct appointment scheduled during the period of study participation, and the appointment cannot be rescheduled for a time before study participation starts or after study participation ends. 9. subject is unsuitable for participation due to any other cause as determined by the investigator.

Keywords: subjects with type 1 or type 2 diabetes requiring multiple daily insulin injection (mdi) or continuous subcutaneous insulin infusion (csii)
reliability, safety and usability of the transplantation sensor system combined with myfortic® in adult kidney transplant patients

Conditions: Detection Accuracy; Patient Compliance

Summary: the main purpose of this exploratory trial is to evaluate the reliability, safety and usability of the transplantation sensor system when the ingestible event marker (iem) is given in combination with ecmps 360 mg tablets in adult renal transplant recipients.


Eligibility criteria:
inclusion criteria: * patients at least 6 months post-transplantation and in stable clinical condition * treatment with ecmps doses between 720 mg/day and 1440 mg/day or mmf doses between1000 mg/day and 2000 mg/day, divided in two equal doses 12 hours apart and with no dose titrations planned for the duration of the trial * ability to independently take medication * successfully ingest a placebo-iem capsule with no difficulty exclusion criteria: * inability to use the mobile phone provided for use in the clinical trial * any episodes of acute rejection in the previous 3 months * presence of cognitive impairment * active alcohol or drug abuse * history of dysphagia, or inflammatory bowel disease, or gastrointestinal conditions or surgery that has modified the normal luminal flow of the gastrointestinal tract (e.g. whipple procedure, bariatric surgery or roux-en-y) * known allergies, including history of skin reactions to patches, that could preclude safe participation in the study other protocol-defined inclusion/exclusion criteria may apply

Keywords: patient compliance ecmps-iem transplantation renal maintenance proteus
active control of prostatic cancer with criteria of latence

Conditions: Prostate Cancer

Summary: this study concern a prospective cohort pf patients with latent prostate cancer. we study the specific survival at 10 years of patients who accept an active control.patients inclusion are realized in 2 stages: * patient with inclusion criteria (psa \< 10 ng/ml, clinical stage t1c or t2a, gleason \< or = 6) are registered if they accept a second prostate biopsy in a 3 months delay * after analyse of second biopsy in central laboratory and confirmation of latent prostate biopsy, patients are included if they accept active control included patients will have 1 biopsy by years the first two years and then 1 biopsy each 2 years during 8 years. if progression of cancer happens during the 10 years control, active control will be stopped and patient will be treated by surgery and chemotherapy.

this study concern the active control during 10 years of patient with latent prostate cancer who accept not be treated immediately.

Eligibility criteria:
inclusion criteria: * patient with a latent prostatic cancer * aged less 75 years old, * life expectation higher than 10 years * clinic statue t1c or t2a * with a seric psa (prostatic specific antigen)smaller than 10ng/ml * more than 10 biopsy cores samples * patient with less than 3 cores samples with tumor and none care sample with more than 3mm of tumor * gleason score inferior at 7 * patient's agreement about project and a second biopsy which will include definitive patient: realized 3 months after the first and having: 14 biopsy cores samples (10 like previously and 4 more specific: taking around the positives initials biopsies), less than 3 cores samples with tumor, ,any cores samples with more than 3mm of tumor, a gleason score superior at 7. exclusion criteria: * patient aged 75 years old and more * no patient's agreement * lack of understanding of plan * patient with guardianship * life expectation smaller than 10 years * patient with an other cancer less than 5 years * local clinical statue greater than t2a * seric psa higher than 10ng/ml * less than 10 biopsies * more than 2 positives biopsies during the first intervention * 3 cores samples with more than 3mm of tumor * 4th grade on the biopsies * patient's refuse to realize the second biopsies * patient who ask a treatment after the first medical examination * patient with less 4 special biopsies around the previously initial cores samples or more than 2 positives biopsies or biopsies with more than 3mm of tumor or patient having a 4 grade on biopsies, during the second medical examination.

Keywords: latent prostate cancer patient with latent prostate cancer psa ≤ 10 ng/ml clinical stage t1c or t2a patient who accept just be control
therapeutic effects of r-idaram and intrathecal immunochemotherapy on elderly patients with pcnsl

Conditions: Primary Central Nervous System Lymphoma

Summary: this study suggests that r-idaram combined with intrathecal immunochemotherapy may be high effective in elderly patients with primary central nervous system lymphoma (pcnsl).

the investigators will evaluate response rate, progression free survival (pfs), overall survival (os), and toxicity in elderly patients with primary central nervous system lymphoma (pcnsl) after systemic and intrathecal immunochemotherapy with deferred radiotherapy.

Eligibility criteria:
inclusion criteria: * newly diagnosed histologically proven non-hodgkin's lymphoma (nhl). exclusion criteria: * involved sites other than the brain, meninges, csf, or the eyes. * age less than 18 years or greater than 75 years. * inadequate bone marrow capacity (defined as neutrophils\<1.5 ×10\^9/l, platelets \<100 ×10\^9/l, and hemoglobin level\< 8 g/dl). * known cause of immunosuppression (ie, hiv type i infection). * any previous malignancy. * creatinine clearance below 60 ml/min. * heart insufficiency (nyha iiib or iv). * uncontrolled infection. * noncompensated active pulmonary or liver disease. * previously treated for pcnsl, except by corticosteroids.
the effect of a high protein diet versus a low fat diet on body weight after smoking cessation

Conditions: Smoking; Overweight; Obesity

Summary: the purpose of this study is to determine whether subjects following a high protein diet will gain less in weight after smoking cessation compared to subjects following a low fat diet due to the effects of protein on metabolic rate and hunger.

sustained smoking cessation is one of the most effective therapies to avoid premature morbidity and mortality. however, weight gain associated with nicotine withdrawal may attenuate some of the beneficial health effects and is cited as a major obstacle to quit smoking. the mechanism for the weight gain is not elucidated but reduced resting metabolic rate, reduced total energy expenditure, increased caloric intake and changes in fat metabolism may be involved. elucidating effective strategies to prevent or reduce post-cessation weight gain may improve health outcomes of smoking cessation.

Eligibility criteria:
inclusion criteria: * smoking 10 cigarettes per day, bmi 25-40 exclusion criteria: * recent change in weight, contra-indications to use varenicline, a medication to assist smoking cessation

Keywords: dietary intervention smoking cessation body weight
recruitment strategies comparing different strategies in sleep apnea and prediabetes

Conditions: Sleep Disorder; Pre Diabetes; Obstructive Sleep Apnea

Summary: recruitment strategies comparing different strategies.

patients with prediabetes and moderate-to-severe obstructive sleep apnea (osa). to determine the recruitment yields from electronic medical record (emr) vs the general community. to assess the adherence to positive airway pressure (pap) therapy among patients with prediabetes and moderate-to-severe osa.

Eligibility criteria:
inclusion criteria: * prediabetes: a1c value of 6.0-6.4% and fasting glucose of 100-125 mg/dl * moderate-to-severe osa \[4% oxygen desaturation index (odi) ≥ 20/h\] * ability to provide informed consent * able to comply with all study procedures and be available for the study duration * availability of smart phone exclusion criteria: * bmi \< 28 or ≥ 38 kg/m2 * type 1 or type 2 diabetes mellitus * pregnancy * use of glucose-lowering or weight loss medications (e.g., metformin, orlistat, phentermine) * prior or anticipated bariatric surgery * current use of pap or oral appliance therapy for osa * commercial driver * report of a motor vehicle accident or near-miss due to sleepiness within 2 years * epworth sleepiness scale score10 \> 18 * current (prevalent) use of oral corticosteroids (within 1 month) * participation in a concurrent clinical trial * unstable medical conditions: uncontrolled angina and/or congestive heart failure, uncontrolled blood pressure or resistant hypertension \[bp ≥ 160/100 among those with hypertension, requiring 3 or more meds\], severe chronic obstructive pulmonary disease, cancer, or active psychiatric disease * other sleep disorders (e.g., circadian rhythm disorder, working night or rotation shift, short sleep duration based on self-reported habitual sleep patterns \< 5 hrs/night) * use of supplemental oxygen during wakefulness or sleep * central sleep apnea (central apnea index ≥ 5/h) or cheyne-stokes respiration (\> 10 minutes of continues period breathing) on the screening home sleep test resting awake spo2 \< 90% * chronic opiate use. * use of illicit drug / marijuana use more than once per week * difficulty understanding or speaking english * anything that, in the opinion of the site investigator, would place the participant at increased risk or preclude a participant's ability to adhere to study protocols or complete the study

Keywords: pre-diabetes sleep apnea pap therapy obstructive sleep apnea
genetic mutations in blood and tissue samples in predicting response to treatment in patients with locally advanced rectal cancer undergoing chemoradiation

Conditions: Mucinous Adenocarcinoma of the Rectum; Recurrent Rectal Cancer; Signet Ring Adenocarcinoma of the Rectum; Stage IIA Rectal Cancer; Stage IIB Rectal Cancer; Stage IIC Rectal Cancer; Stage IIIA Rectal Cancer; Stage IIIB Rectal Cancer; Stage IIIC Rectal Cancer

Summary: this research trial studies genetic mutations in blood and tissue samples to see if they can be used to predict treatment response in patients with locally advanced rectal cancer undergoing chemoradiation. studying samples of blood and tumor tissue in the laboratory from patients with cancer may help doctors learn more about genetic mutations or changes that occur in deoxyribonucleic acid (dna) and help doctors understand how patients respond to treatment.

primary objectives: i. to evaluate the tumor-specific mutation(s) detected using the cancercode™ mutation panel as a predictor of pathologic response to chemoradiation for patients with rectal adenocarcinoma undergoing chemoradiation. secondary objectives: i. to assess the feasibility of utilizing biopsy specimens from locally advanced rectal adenocarcinoma to perform cancercode™ mutation panel genetic testing. ii. to assess disease-free survival (dfs) and overall survival (os) of patients treated on study. iii. to collect pilot data regarding the clonal heterogeneity of rectal adenocarcinoma, and the relationship of this heterogeneity with treatment response. iv. to evaluate the treatment response utilizing multiple fludeoxyglucose f 18-positron emission tomography (fdg-pet) parameters including heterogeneity and textural features as an exploratory study. outline: patients undergo collection of blood and tissue samples for analysis via sequencing. after completion of study, patients are followed up every 3 months for 3 years.

Eligibility criteria:
inclusion criteria: * locally advanced rectal adenocarcinoma: t3-4nanym0 or tanyn1-2m0 * radiologically measurable or clinically evaluable disease * provide informed written consent * willing to return to enrolling medical site for all study assessments exclusion criteria: * chemotherapy within 5 years prior to registration; (hormonal therapy is allowable if the disease free interval is \>= 5 years) * any prior pelvic radiation * patients who are at high risk of complications from temporarily discontinuing anticoagulation for rectal cancer biopsies
a clinical study to evaluate the safety and efficacy of the flostent in men with benign prostatic hyperplasia symptoms

Conditions: Benign Prostatic Hyperplasia

Summary: the goal of this study is to determine the safety and effectiveness of the flostent, a medical device used to treat men with symptoms of benign prostatic hyperplasia, compared to sham (procedure without deployment of the flostent). all participants will undergo a flexible cystoscopy and those randomized to the treatment arm will receive the flostent, while those randomized to the sham arm will not receive the flostent.


Eligibility criteria:
inclusion criteria: * male subjects \> 45 years of age who have symptomatic bph * international prostate symptom score (ipss) score \>13 * peak urinary flow rate (qmax): \>5 ml/sec and \ 125 ml * post-void residual (pvr) \<250 ml * prostate volume 25 to 80 ml * prostatic urethral length 20-50 mm * able to complete the study protocol and visits exclusion criteria: * presence of an artificial urinary sphincter or stent(s) in the urethra or prostate * prior minimally invasive intervention or surgical intervention of the prostate or urethra * psa \>10 ng/ml * bladder cancer or bladder stones * active urinary tract infection (uti) * uncontrolled diabetes * part of a vulnerable population (cognitively challenged or are incarcerated)

Keywords: benign prostatic hyperplasia flostent rivermark medical bph luts lower urinary tract symptoms enlarged prostate
mindfulness-based yoga intervention for women with depression

Conditions: Depression; Depressive Symptoms

Summary: the purpose of this study was to examine the efficacy of a 12-week mindfulness-based yoga intervention on depressive symptoms and rumination among depressed women.

this study was a prospective, randomized controlled intervention pilot study conducted in a metropolitan city in the upper midwest of the united states. forty women who met the criteria for depression based on the structured clinical interview for diagnostic and statistical manual of mental disorders iv (scid-i; first, spitzer, gibbon, \& williams, 1997)were randomized to an experimental mindfulness-based yoga condition (n=20) or a walking control condition (n=20). both programs were home-based motivational sessions delivered over the telephone and lasted 12 weeks. assessments were conducted at baseline, three months (i.e., post-intervention), one-month follow-up (i.e., one month after the intervention ended). participants were instructed to continue their usual depression care. the primary dependent variable was depressive symptoms based on the beck depression inventory (bdi). the secondary dependent variable was rumination scores on the ruminative responses scale (rrs). this protocol was approved by the university of minnesota's institutional review board (irb). participants completed informed consent forms sent through the mail; consent to participate in physical activity was also obtained from the participant's healthcare provider. recruitment for this trial occurred from february, 2013 to january, 2014 and follow-up assessments were completed by may, 2014.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * a personal history of depression (i.e., ever being told by a healthcare provider that they had depression or given an antidepressant for depression) * able to read and write in the english language * able to commit to two sessions (yoga or walking) per week for 12 weeks * demonstrate a willingness to be randomly assigned to either of the study arms * be yoga naïve, defined as not taking more than four yoga classes in the past two years and not more than one class in the past month. exclusion criteria: * individuals with a history of bipolar disorder or schizophrenia and/or who had been hospitalized for a psychiatric disorder within six months prior to the eligibility screening * individuals not providing signed informed consent * individuals reporting any other health problems that would interfere with regular yoga practice or walking sessions * individuals who engaged in more than 90 minutes of moderate intensity physical activity per week during the month prior to the eligibility screening.

Keywords: depression yoga mindfulness
immediate loading of dental implants: a pilot clinical study

Conditions: Dental Implantation

Summary: objective: to provide 2-year clinical- and patient-oriented data with regard to mandibular overdenture assisted by 2 immediately loaded unsplinted implants.

in this pre-post design, phase-i clinical trial, 18 edentate individuals received a new set of complete denture. then, following standard procedures, 3 threaded implants (osseospeed txtm, dentsply implants, mölndal, sweden) were placed in the mandible in each patient, and locator abutments (zest anchors llc, escondido, u.s.a.) were inserted on the right and left side implants. the midline implant served as a control for within-patient comparison. the immediate loading was conducted within 24 h of surgery. data were collected at baseline (t0), 12 (t1) and 24 (t2) months after immediate loading. the clinical outcomes included implant survival rate, crestal bone level changes and implant stability. these criteria were assessed through clinical and radiographic examinations as well as resonance frequency analysis. patient-centered outcomes included patient satisfaction and oral health-related quality of life measured using validated questionnaires. brunner-langer approach was used for statistical analysis.

Eligibility criteria:
inclusion criteria: * minimal age of 18 years * complete edentulism for more than 1 year * wear of total conventional prosthesis for more than 1 year * bone morphology in the anterior mandibular region amendable for the placement of 3 regular diameter implants without any additional procedure (graft or membrane). exclusion criteria: * any absolute or relative contra-indication to implant therapy * physical incapacity to render oral or prosthetic hygiene * incapacity to obtain a free and informed consent * incapacity to assist to planned follow up appointments * incapacity to understand and complete questionnaires exclusion criteria to immediate loading protocol found on one or both of un-splinted implants during surgery: * inadequate bone quality: it\<35 ncm * inadequate primary stability: isq\<60

Keywords: immediate-loading patient-based outcomes